Full Press Release Details
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
LEXINGTON, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF- ") family of proteins, today announced that Keros' Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will present at the following healthcare conferences
Morgan Stanley 22nd Annual Global Healthcare Conference
Date and Time Wednesday, September 4, 2024 at 4 05 p.m. Eastern time
Link https cc.webcasts.com morg007 090424a_js entity 151_MYXXV3G
Format Fireside Chat Presentation
2024 Wells Fargo Healthcare Conference
Date and Time Thursday, September 5, 2024 at 10 15 a.m. Eastern time
Link https cc.webcasts.com well001 090424a_js entity 90_NG8VPD0
Format Fireside Chat Presentation
2024 Cantor Global Healthcare Conference
Date and Time Thursday, September 19, 2024 at 8 35 a.m. Eastern Time
Link https wsw.com webcast cantor22 kros 2112021
Format Fireside Chat Presentation
For each presentation, an archived replay will be accessible in the Investors section of the Keros website at https ir.kerostx.com for up to 90 days following the conclusion of each event.
About Keros Therapeutics, Inc.
Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF- family of proteins. The Company is a leader in understanding the role of the TGF- family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros' lead product candidate, elritercept (KER-050), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros' second product candidate, cibotercept (KER-012), is being developed for the treatment of pulmonary arterial hypertension for the treatment of cardiovascular disorders.
Keros' third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases.